Navigation Links
ImmunoVaccine Technologies Signs Agreement with National Institutes of Health to Explore Vaccines for HIV and Malaria
Date:2/25/2009

HALIFAX, NS, Feb. 25 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, has signed a collaborative agreement with the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH), in Maryland, USA. The research collaboration involves formulating NIAID antigens in DepoVax(TM), IVT's vaccine enhancement system, and exploring potential vaccines for HIV and malaria.

"NIAID is a world leader in the study of infectious and immune-mediated disease, and we look forward to seeing how our enhanced DepoVax(TM) delivery system augments this research," said Dr. Marc Mansour, vice president of R&D at IVT.

There are currently a limited number of vaccine formulations capable of inducing potent and durable T cell responses. Several vaccines in development, based on replication-defective adenovirus, are limited in their ability to be used repeatedly. There is an urgent need to develop protein vaccines that can induce antibody and T cell responses, and be used in combination with other vaccines. The goal of this pre-clinical research collaboration is to establish whether a novel vaccine formulation, in which a specified protein is formulated in DepoVax(TM), will induce stronger T cell responses compared to other protein-based formulations. Proteins from HIV, SIV and malaria will be tested.

ABOUT IVT

ImmunoVaccine Technologies Inc., winner of Canada's Top 10 Life Sciences Companies, is a privately held, vaccine development company. Through its own biotech research, patented VacciMax(R) and DepoVax(TM) technologies, and collaborations with partners, IVT creates vaccines with the potential to help save and improve lives around the world.

www.immunovaccine.com.

ABOUT NIAID and NIH

NIAID conducts and supports research-on the NIH campus, throughout the United States, and worldwide-to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. www.niaid.nih.gov. The National Institutes of Health (NIH)-The Nation's Medical Research Agency-includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. www.nih.gov.


'/>"/>
SOURCE ImmunoVaccine Technologies Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ImmunoVaccine Technologies Presents at OneMed Place Finance Forum
2. ImmunoVaccine Technologies Broadens Its Patent Protection to Japan
3. ImmunoVaccine Technologies Congratulates Dr. Ramila Philip as One of PAs Best 50 Women in Business
4. ImmunoVaccine Technologies Patents DepoVax(TM) Vaccine Platform
5. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
6. ImmunoVaccine Technologies Inc. Nears Phase I Clinical Trials with Completion of Scientific Advisory Board
7. BioNanomatrixs Revolutionary Whole Genome Analysis Platform Named to MIT Technology Reviews Annual 10 Emerging Technologies List
8. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
9. Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
10. Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results
11. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Sequenom, Inc. (NASDAQ: SQNM ), ... through the development of innovative products and services, announced ... United States denied its petition to review ... Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") are not ... the Supreme Court,s Mayo Collaborative Services v. Prometheus Laboratories ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
Breaking Biology Technology:
(Date:6/22/2016)... On Monday, the Department of Homeland Security (DHS) issued ... the Biometric Exit Program. The Request for Information (RFI), ... that CBP intends to add biometrics to confirm when ... , in order to deter visa overstays, to ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
Breaking Biology News(10 mins):